Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001610717-25-000369
Filing Date
2025-10-29
Accepted
2025-10-29 16:49:49
Documents
2
Period of Report
2025-10-20

Document Format Files

Seq Description Document Type Size
1 form3.html 3  
1 form3.xml 3 1506
2 POWER OF ATTORNEY poa.htm EX-24.1 7141
  Complete submission text file 0001610717-25-000369.txt   10136
Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Issuer) CIK: 0001501989 (see all company filings)

EIN.: 273521219 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O CYTOMX THERAPEUTICS, INC. 151 OYSTER POINT BLVD., SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address
Lester Rachael (Reporting) CIK: 0002094324 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-37587 | Film No.: 251430646